Loc Vo
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1033615216
Payments from drug & device makers
Across 255 payments — averaging $26.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$831
- Lilly USA, LLC$784
- Mannkind Corporation$506
- Sanofi-aventis U.S. LLC$460
- Bayer$446
- Novo Nordisk$444
- plus $3K from 32 others
What the payments were for
- Consulting fees$1753%
- Food & beverage$6,57697%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $831 |
| Lilly USA, LLC | 33 | $784 |
| Mannkind Corporation | 16 | $506 |
| Sanofi-aventis U.S. LLC | 14 | $460 |
| Bayer | 18 | $446 |
| Novo Nordisk | 20 | $444 |
| AbbVie | 18 | $442 |
| Corcept Therapeutics | 14 | $302 |
| Ascendis Pharma Endocrinology Inc | 5 | $227 |
| Pfizer | 9 | $223 |
| Exact Sciences | 7 | $198 |
| AstraZeneca(2 entities) | 8 | $160 |
| Antares Pharma, Inc. | 6 | $148 |
| Kyowa Kirin, Inc. | 8 | $139 |
| Lundbeck LLC | 7 | $136 |
| Intuity Medical Inc | 6 | $134 |
| Astellas Pharma US Inc | 4 | $125 |
| Hologic Sales And Service, LLC | 1 | $102 |
| Novartis | 3 | $87 |
| Xeris Pharmaceuticals, Inc. | 4 | $83 |
| Amneal Pharmaceuticals LLC | 3 | $74 |
| Radius Health, Inc. | 3 | $71 |
| Recordati_rare_diseases_inc. | 3 | $67 |
| Acella Pharmaceuticals, LLC | 3 | $65 |
| Intra-sana Laboratories | 3 | $61 |
| Neurocrine Biosciences, Inc. | 2 | $57 |
| Insulet Corporation | 2 | $56 |
| Madrigal Pharmaceuticals | 2 | $52 |
| Dexcom, Inc. | 2 | $51 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Eisai Inc. | 1 | $32 |
| Halozyme Inc | 1 | $27 |
| Tandem Diabetes Care, Inc. | 1 | $25 |
| IBSA Pharma Inc. | 1 | $24 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $21 |
| Tolmar, Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$250
- Prolia$175
- AFREZZA$150
- CoolSeal Generator$102
How this compares
$6,751 in reported general payments places this provider in the 70th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 20 | $42,694 |
| JardianceEmpagliflozin | 20 | $31,807 |
| Levothyroxine Sodium | 43 | $562 |
| Metformin Hcl ErMetformin Hcl | 19 | $278 |
| Methimazole | 13 | $168 |
| Metformin Hcl | 11 | $100 |
| Alendronate Sodium | 22 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $444 | $42,69420 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $74 | $56243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- Anastasios ManessisNew York$4.4M
- Adi CohenNew York$2.5M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Henry GinsbergNew York$1M
- John BilezikianNew York$814K
- Eliza GeerNew York$760K
- Christoph BuettnerNew York$709K
- Emily SteinNew York$489K
- Jason BakerNew York$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.